Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs United Airlines Holdings Inc (UAL) Price & Performance

BioNTech SE - ADRTrade
United Airlines Holdings IncTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs United Airlines Holdings Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while United Airlines Holdings Inc trades at $124.88 (market cap $41.00B). The key difference: United Airlines Holdings Inc is the larger of the two by market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXUAL
Market Cap
$23.31B$41.00B
Sector
HealthIndustrials
52-Week High
$119.34$136.11
52-Week Low
$83.89$85.21
Enterprise Value
$6.60B$58.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.

The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.

United Airlines Holdings Inc

United Airlines (UAL) trades at $123.76, down 4.48% today, but maintains a bullish technical signal with strong analyst support. The stock shows robust fundamentals, including a P/E of 11.83, net income margin of 5.56%, and three consecutive quarterly EPS beats. Revenue growth is steady, rising to $59.07B in 2025, with cash flow from operations at $8.43B. Recent news highlights CEO Scott Kirby's focus on innovation after merger attempts failed, while industry-wide fuel cost pressures are being managed.

Outlook remains positive with a consensus price target of $167.73, implying 35% upside. Opportunities include strong travel demand and operational efficiency, but risks involve volatile fuel prices, competitive pressures, and execution challenges. Wall Street sentiment is bullish with 66% buy ratings and no sell recommendations, supporting a favorable risk-reward profile for long-term investors.

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About United Airlines Holdings Inc

United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.

Read more on UAL